



	GENE(S)	ASSOCIATED CANCER RISKS
ColonNext	<i>BMPRI1/SMAD4</i> *	Colorectal (40-50%), stomach (up to 21%)
	<i>CDH1</i> *	Diffuse gastric (67-83%), female lobular breast (39-52%), colorectal
	<i>GREM1</i> *	Colorectal
	<i>MUTYH</i> *	Biallelic mutations: colorectal (up to 80%), stomach, duodenal, uterine, breast Monoallelic mutations: breast, colorectal (up to 2 fold)
	<i>POLD1/POLE</i> *	Colorectal
	<i>PTEN</i> *	Breast (25-85%), thyroid (10-35%), uterine (5-28%), melanoma (up to 6%), other
	<i>EPCAM</i> *,**	Colorectal (52-82%), uterine (12-55%), possibly prostate, other
	<i>MLH1</i> *,**	Colorectal (52-82%), uterine (25-60%), stomach (6-13%), ovarian (4-12%), prostate (2 fold), other
	<i>MSH2</i> *,**	Colorectal (52-82%), uterine (25-60%), stomach (6-13%), ovarian (4-12%), prostate (2 fold), other
	<i>MSH6</i> *,**	Colorectal (20-44%), uterine (up to 44%), prostate (2 fold), other
	<i>PMS2</i> *,**	Colorectal (15-20%), uterine (15%), possibly prostate, other
	<i>APC</i> *	Colorectal (up to 100%), small bowel, stomach, pancreatic, thyroid, brain, other
	<i>STK11</i> *	GI cancers (up to 57%) breast (up to 45%), pancreatic, other
	<i>TP53</i> *	Breast, sarcoma, brain, adrenocortical, leukemia, other
	PancNext	<i>ATM</i> *
<i>CDKN2A</i>		Melanoma (28-67%), pancreatic (17-25%), brain
<i>BRCA1</i> *		Female breast (57-87%), ovarian (39-40%), pancreatic, melanoma, prostate, male breast
<i>BRCA2</i> *		Female breast (45-84%), ovarian (11-18%), pancreatic, melanoma, prostate (15%), male breast (>6%)
<i>PALB2</i> *		Breast (33-58%), pancreatic, ovarian, possibly prostate, male breast
<i>BARD1</i>		Breast, possibly ovarian
<i>BRIP1</i> *		Ovarian (up to 9%), breast
<i>CDK4</i>		Melanoma (up to 74% by age 50)
<i>MRE11A</i>		Breast, possibly ovarian
<i>NBN</i> *		Breast, possibly ovarian, brain, prostate
CancerNext	<i>NF1</i> *	Breast (3-5 fold), malignant nerve sheath tumors (8-13%), PGL/PCC (up to 7%), brain, other
	<i>RAD50</i>	Breast, possibly ovarian
	<i>RAD51C</i> *	Ovarian (5-9%), breast
	<i>RAD51D</i> *	Ovarian (10-12%), breast, prostate
	<i>SMARCA4</i>	Ovarian (small cell carcinoma, hypercalcemic type), brain, other

\* NCCN® management guidelines available, excludes *MUTYH* monoallelic mutations

\*\* Lynch syndrome